Semaglutide market is booming, but illegal sales and counterfeit drugs pose challenges

August 19, 2024

Semaglutide, a GLP-1 receptor agonist, has gained significant attention for its dual role in managing type 2 diabetes and facilitating weight loss. Originally developed by Novo Nordisk, semaglutide has seen rapid adoption due to its effectiveness in improving glycemic control and aiding in weight management. The drug operates by enhancing insulin secretion, reducing glucagon secretion, and slowing gastric emptying, leading to reduced appetite and weight loss. The success of semaglutide has expanded its use from diabetes management to obesity treatment, with different formulations marketed under brand names like Ozempic, Rybelsus, and Wegovy.

The market performance of semaglutide-related companies, particularly Novo Nordisk and Eli Lilly, has been outstanding. In the first half of 2024, Novo Nordisk reported a 24% year-on-year increase in revenue, driven by the strong sales of its semaglutide products. Ozempic, Rybelsus, and Wegovy collectively brought in $12.6 billion, with Wegovy's sales alone growing by 74% year-on-year. Similarly, Eli Lilly, benefiting from the success of its GLP-1 drug tirzepatide, reported a 31% increase in revenue for the first half of 2024. The fierce competition between these companies has narrowed the gap between Novo Nordisk's semaglutide products and Merck's leading drug Keytruda, underscoring semaglutide's growing market significance.

However, semaglutide has faced challenges in the U.S. market, primarily due to the rise of illegal sales and counterfeit drugs. The high demand and price of semaglutide, with monthly treatment costs around $1,000, have led to the proliferation of "compounded" versions, which are often cheaper but not FDA-approved. These unregulated products, sometimes mixed with other substances, pose significant health risks, as their safety and efficacy are not guaranteed. The U.S. FDA has issued multiple warnings about these products, and Novo Nordisk has taken legal action to combat the counterfeit market, filing over 30 lawsuits in an effort to protect consumers and maintain market integrity. Despite these efforts, the illegal sale of semaglutide and related compounds remains a significant issue, highlighting the need for stronger regulatory oversight.